7/28/2019 Nuevos Targets en Osteoporosis
1/8
20 nature clinical practice RHEUMATOLOGY jAnUARY 2009 vOL 5 nO 1
www.nature.com/clinicalpractice/rheum
Potential new drug targets for osteoporosisChad Deal
INTRODUCTION
Osteoporosis is a worldwide health problem thataffects as many as 75 million people in the US,Japan and Europe. Fracture is the most commoncomplication of osteoporosisit is estimatedthat 3050% of women and 1530% of menwith this disease have a fracture during their life-time. Osteoporosis accounts for more hospitaldays than diabetes, breast cancer or myocardial
infarction.
1
Bone remodeling facilitates repair ofmicrodamage and provides calcium from bonestores for cellular functions (Figure 1). The meta-bolic component of bone is made up of boneremodeling units (BRUs), over 1 million ofwhich are active at any given time in a healthyadult woman.It is estimated that complete turn-over of the skeleton occurs every 10 years. Boneremodeling is, however, accelerated in post-menopausal women, in whom estrogen defi-ciency results in increased bone turnover withan excess of resorption over formation. The factthat bone remodeling is an active and dynamicprocess enables the use of interventions in thetreatment of osteoporosis that limit resorption(antiresorptive therapy) or augment formation(anabolic therapy).2
The activity of BRUs follows a well choreo-graphed sequence of events. In the initial step,osteoclasts reabsorb bone over a period of about3 weeks to create resorption cavities, whichare collectively termed the remodeling space.Resorption is followed by osteoblast activationand formation of osteoid, which fills the resorp-tion cavities over a period of about 3 months.
When this active matrix synthesis is finished,osteoblasts become embedded in the matrixand function as osteocytes. These cells remainactive in bone remodeling by maintainingconnections to the bone surface, the BRUs andother osteocytes via an extensive canalicularnetwork. Fluid flows through this network andis thought to induce signaling, thus permittingosteocytes to function as mechanoreceptors.Osteocytes are able to direct remodeling toareas that require repair.3
SuMMarY
Osteoporosis is a worldwide health problem with a high prevalence. Agentsfor the treatment of osteoporosis are classified as either antiresorptive oranabolic. Antiresorptive agents work by inhibiting the activity of osteoclastsand, therefore, reducing bone resorption. Currently available antiresorptiveagents include bisphosphonates, selective estrogen-receptor modulators,calcitonin and estrogen. Various novel antiresorptive agents are indevelopment. Receptor activator of nuclear factor B ligand is an importantcytokine involved in osteoclast activation; denosumab, a fully human
monoclonal antibody to this molecule, has finished a major fracture trial.Assessment is underway of odanacatiban inhibitor of cathepsin K, whichis an osteoclast enzyme required for resorption of bone matrix. Glucagon-like peptide 2 is being evaluated for the prevention of the nocturnal risein bone resorption without affecting bone formation. Anabolic agents act
by stimulating formation of new bone. The only anabolic agent currentlyavailable in the US is teriparatiderecombinant human parathyroidhormone (PTH)134and recombinant human PTH184 is available inEurope. PTH stimulates osteoblast function and bone formation. Novelanabolic agents in development include: antibodies such as sclerostin anddickkopf-1 that target molecules involved in Wnt signaling, a pathway thatregulates gene transcription of proteins that are important for osteoblastfunction; an antagonist to the calcium-sensing receptor; and an activinreceptor fusion protein, which functions as an activin antagonist and hasshown promise as an anabolic agent in early human trials.
Keywords anablic agnt, antiptiv agnt, calcium-ning cpt,tpi, wnt ignaling
C Deal is Head of the Center for Osteoporosis and Metabolic Bone Diseaseat the Orthopedic and Rheumatology Institute, Cleveland Clinic, Cleveland,OH, USA.
CorrspondncCenter for Osteoporosis and Metabolic Bone Disease, Orthopedic and Rheumatologic
Institute (A50), Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Rcid 6 May 2008 Accptd 12 November 2008
www.nature.com/clinicalpractice
doi:10.1038/ncprheum0977
RevIew CRITeRIAA review of the literature was performed by searching PubMed using thefollowing search terms antiresorptive agents, anabolic agents, Wnt signaling,calcium sensing receptor and novel osteoporosis therapies. Abstracts andfull-text papers published between 2000 and 2008 were reviewed.
review
http://www.nature.com/clinicalpractice/cardiomailto:[email protected]://www.nature.com/clinicalpractice/cardiohttp://www.nature.com/doifinder/10.1038/ncprheum0977http://www.nature.com/doifinder/10.1038/ncprheum0977http://www.nature.com/clinicalpractice/cardiomailto:[email protected]://www.nature.com/clinicalpractice/cardio7/28/2019 Nuevos Targets en Osteoporosis
2/8
jAnUARY 2009 vOL 5 nO 1 DEAL nature clinical practice RHEUMATOLOGY 21
www.nature.com/clinicalpractice/rheum
The therapies currently available to modifybone remodeling and, therefore, treat osteo-porosis all have limitations. Treatment withantiresorptive agents, for example, eventuallyleads to a decrease in osteoblast function. Theinitial increase in bone mass that results fromthe use of this type of therapy is due to inhibi-tion of bone resorption by osteoclasts, whileosteoblasts continue to function and fill in theremodeling space. This uncoupling of formationand resorption, however, lasts for only a shorttime (about 2 years) before osteoblast func-tion decreases and accumulation of bone massbegins to slow. Increases in bone mass after thistime point are largely related to an increase inmineralization densitya result of reducedbone turnover. Bisphosphonatesa type ofantiresorptive agenthave a long half life inbone; after discontinuation of therapy a residualamount of drug remains in bone and is availableto osteoclasts in the future when further BMUsare activated. In rare cases, long-term therapymight lead to turnover being inadequate to repairmicrodamage, at which point bone is referred
to as being adynamic.4 This low turnover stateis thought to result in the accumulation andcoalescence of microcracks, which results in frac-tures.4 For the anabolic agent teriparatide, use islimited to 24 months in the US and 18 monthsin Europe, as the clinical trial of this agent wasdiscontinued after a mean treatment duration of19 months because an animal toxicology studyshowed an increased incidence of osteosarcoma.5Evidence from more than 6 years of clinical use,however, indicates that the development of
osteosarcoma does not seem to be increased withthe use of teriparatide.
Research is currently focusing on drugs thattarget the remodeling cycle by affecting osteo-blasts, osteoclasts and osteocytes, and/or mole-cules that control signaling pathways importantfor cell function and gene transcription. Thegoal of this article is to review the types andmodes of action of therapies that are currentlyavailable and those that are in development forthe treatment of patients with low bone mass.
ANTIReSORPTIve AGeNTS
Bisphosphonates are the most frequently usedtype of antiresorptive agent. These drugs bindavidly to hydroxyapatite and work by inhibitingfarnesyl pyrophosphate synthase, an enzymein the mevalonate pathway (Box 1).6,7 Thispathway is important for protein prenylationthe attachment of lipids to proteinswhich iscritical for cytoskeletal organization in osteo-clasts. Inhibition of the mevalonate pathwaydisrupts cytoskeletal structure, which preventsosteoclasts from forming a ruffled border on
the bone during the remodeling process, genera-ting a proton gradient, and resorbing mineralsand matrix.
Bone resorption and formation are tightlycoupled. As described above, inhibition ofresorption eventually results in inhibition of for-mation. An agent that inhibits bone resorptionbut allows bone formation to continue would,therefore, have a greater effect on bone massand quality than currently available agents. Micethat lack the chloride channel CLC-7 have no
Resting
bonesurface Resorption
Activation
Reversal
OCprecursor
OBprecursor
Mononuclearcells
~3 weeks ~3 months
OC OB
Bone formation Mineralization
BRUOSCL
LC
Figur 1 The sequence of bone remodeling in healthy individuals. Remodeling is initiated when osteoclasts
are activated, resorb bone and create resorption cavities. Resorption is followed by osteoblast activation
and formation of osteoid, which then fills in the resorption cavity. This active process is the target of
pharmaceutical agents that affect bone resorption and formation. Abbreviations: BRU, bone remodeling unit;
CL, cement line; LC, lining cells; OB, osteoblast; OC, osteoclast; OS, osteoid.
review
http://www.nature.com/clinicalpractice/cardiohttp://www.nature.com/clinicalpractice/cardio7/28/2019 Nuevos Targets en Osteoporosis
3/8
22 nature clinical practice RHEUMATOLOGY DEAL jAnUARY 2009 vOL 5 nO 1
www.nature.com/clinicalpractice/rheum
functional osteoclasts and thus have reducedbone resorption, but do have ongoing boneformation. This finding suggests that the develop-ment of an agent that inhibits bone resorptionbut permits bone formation could be possible.8
Glucagon-like peptide 2
Glucagon-like peptide 2 (GLP-2) is a polypeptide
hormone released from the intestinal mucosa inresponse to food intake. Bone remodeling occursaccording to a circadian rhythm, with bone resorp-tion rising in the night.9 The rhythm is affected bythe rate of food intake, for example by nocturnalfasting. Treatment with GLP-2 at bedtime resultsin a substantial reduction in the bone resorptionthat normally occurs overnight. GLP-2 does notseem to reduce bone formation, as evidenced bystable levels of osteocalcina marker of boneformationduring treatment.10,11 A 120-day
phase II trial of GLP-2 in 160 postmenopausalwomen demonstrated an increase in hip bonemineral density (BMD) and a reduction inthe nocturnal rise in the concentration of C-telopeptidea marker of bone resorptionwithno effect on osteocalcin.10,11 If this pattern could
be sustained in the long term, GLP-2 would have anadvantage over currently available antiresorptiveagents, which decrease bone formation.
Cathepsin K inhibitors
Cathepsin K is a cysteine protease that is selec-tively expressed by osteoclasts and can degradekey bone matrix proteins, including collagen.12Elimination of cathepsin K in osteoclasts resultsin inhibition of bone resorption. Inhibitors of cat-hepsin K are suggested to have less of an effect onosteoclastosteoblast interaction than available
bisphosphonate antiresorptive agents, resultingin less inhibition of bone formation.The first demonstration of the effect of cat-
hepsin K inhibitors on BMD in humans wasin a 12-month trial of balicatib in 675 post-menopausal women with BMD T scores of lessthan 2.0.13 In this study, markers of bone resorp-tion declined by 5561%, with no decline inmarkers of bone formation. BMD in the lumbarspine increased by 4.4% and in the hip by 2.2%.Skin reactions, including pruritis and morphea-like changes, were noted in a small number ofpatients. In addition, balicatib increased intactparathyroid hormone (PTH) levels by 50% in asmall Japanese trial.14
Owing to adverse effects, especially skinreactions, drug development of all cathepsin Kinhibitors except for odanacatib (formerly MK-0822) has been suspended. Cathepsin inhibi-tors other than odanacatib seem less specific forcathepsin K, which may account for the apparentdifferences in toxicity. Inhibition of cathepsin Kin humans by orally bioavailable odanacatib isbeing evaluated in several ongoing trials. The 24-month results of a randomized controlled trial
evaluating four doses of odanacatib given as adaily oral dose showed increases in spine andhip density (5.5% and 3.2%, respectively). UrineN-telopeptide of type I collagen (uNTX) andbone-specific alkaline phosphatase (BSAP)decreased 52% and 13%, respectively, in patientson odanacatib, whereas uNTX decreased by 5%and BSAP increased by 3% with placebo. Thesefindings suggest that odanacatib produces lessinhibition of bone formation than seen withcurrent antiresorptive therapies.15
Box 1 Mechanism of action of nitrogen-
containing bisphosphonates.
Nitrogen-containing bisphosphonatessuch as
risedronate sodium, zoledronic acid, disodium
pamidronate, alendronic acid and ibandronic
acidwork predominantly by inhibiting the enzyme
FPPS, which catalyzes a step in the mevalonate
pathway and inhibits protein prenylation.
Protein prenylation involves the transfer of a
farnesyl or geranylgeranyl isoprenoid lipid group
onto the C-terminus of small GTPases. The
GTPases are critical for osteoclast proliferation,
apoptosis, membrane ruffling and membrane
trafficking. Loss of these prenylated proteins
in cell membranes results in loss of osteoclast
function. Abbreviations: HMG-CoA, hydroxy-
3-methylglutaryl coenzyme A; FPP, farnesyl
pyrophosphate; FPPS, farnesyl pyrophosphate
synthase; GGPP, geranylgeranyl diphosphate;
GTP, guanine triphosphate.
Nitrogen-containingbiophosphonates inhibitFPPS
RhoGGPP
FPP
Cholesterol
Squalene
Mevalonate
HMG-CoA
Rab
C20
Ras
C15
Rac
review
http://www.nature.com/clinicalpractice/cardiohttp://www.nature.com/clinicalpractice/cardio7/28/2019 Nuevos Targets en Osteoporosis
4/8
jAnUARY 2009 vOL 5 nO 1 DEAL nature clinical practice RHEUMATOLOGY 23
www.nature.com/clinicalpractice/rheum
Denosumab
Receptor activator of nuclear factor B ligand(RANKL), a member of the TNF receptor family,is an important mediator of bone remodelingand is expressed by various cell types, includingosteoblasts, synovial fibroblasts and activatedT cells. RANKL binds to receptor activator ofnuclear factor B (RANK) on osteoclast mem-branes and induces differentiation, activationand survival of these cells.16,17 A regulatorof RANKRANKL interaction is the solublecytokine osteoprotegerin, which is a naturallyoccurring member of the TNF receptor familythat acts as a decoy receptor by competing withRANKL for the bind sites of RANK (Figure 2).Denosumab is a human monoclonal IgG2 anti-body that binds selectively and with high affinityto RANKL and pharmacologically mimics theeffect of osteoprotegerin on RANKL. The results
of a phase II randomized dose-ranging trialevaluating denosumab have been reported.18At 24 months, increases in lumbar spine densityranging from 4.1% to 8.9% were observed.BMD gains at cortical sites, such as the hip andforearm, were greater with denosumab than withalendronic acid. No patient developed neutraliz-ing antibodies during the trial. A 3-year phase IIIfracture trial examining denosumab administeredsubcutaneously in 60 mg doses every 6 monthsdemonstrated 68%, 41% and 20% reductions
in vertebral, hip and nonvertebral fractures,respectively, compared with placebo.19
Denosumab differs from bisphosphonatesin several ways. First, levels of bone turnovermarkers nadir more rapidly, within a few days ofinjection, after denosumab treatment than follow-ing bisphosphonate therapy; after discontinu-ation, bone markers recover to normal levelsmore rapidly than with oral bisphosphonates.Second, there is no accumulation of denosumabin the bone, as there is with bisphosphonates.A third potential difference is that combiningdenosumab with PTH therapy could, in theory,have an additive effect on BMD. This effect isseen in animal models when osteoprotegerinis added to PTH therapy and is in contrast to theeffect seen with the addition of bisphosphonates,which blunts the PTH response.
ANABOLIC AGeNTS
Anabolic agents have the capacity to increasebone mass to a greater degree than antiresorptiveagents. Not only are anabolic agents able toincrease bone mass, but they also have thecapacity to improve bone quality and increasebone strengthin part by affecting micro-architectural features such as connectivity, densityand geometric features. These changes in qualitycannot, however, be detected by current clinicalmeasures of drug response, such as assessment
Osteoblastlineage
Growth factors,hormones,cytokines
RANKL
RANKL
RANK
OPG
Denosumab
Colony-formingunit macrophage
Prefusionosteoclast
Multinucleated
osteoclast
Bone
OC
Figur 2 Proposed mechanism of action for denosumab. Denosumab is an investigational, fully human
monoclonal antibody that binds with high affinity to and inhibits the activity of human RANKL, a key
mediator of osteoclast activity. RANKL is an essential mediator of the formation, activation and survival
of osteoclasts. Denosumab does not bind to other TNF receptors, including TRAIL. Abbreviations:OPG, osteoprotegerin; RANK, receptor activator of nuclear factor B; RANKL, receptor activatorof nuclear factor B ligand; TRAIL, TNF-related apoptosis-inducing ligand.
review
http://www.nature.com/clinicalpractice/cardiohttp://www.nature.com/clinicalpractice/cardio7/28/2019 Nuevos Targets en Osteoporosis
5/8
24 nature clinical practice RHEUMATOLOGY DEAL jAnUARY 2009 vOL 5 nO 1
www.nature.com/clinicalpractice/rheum
of levels of bone turnover markers and dualX-ray absorptiometry. When quantitative CT,a volumetric measure of bone mass, is used tomeasure change in BMD during PTH treatment,the increases observed are substantially greaterthan those seen with dual X-ray absorptio-metry, an area measure of bone mass. The useof quantitative CT to measure drug response inclinical practice is, however, prevented by the costof this technique and the concern regarding theintensity of radiation required.
Parathyroid hormone
The recombinant human PTH134 teriparatide isthe only anabolic agent currently available in theUS for the treatment of patients with low bonemass, and recombinant human PTH1-84 is avail-able in Europe.20 The mechanism of action ofrecombinant human PTH is still under investi-gation, but the drug probably affects multiplepathways and alters the activity of osteoblasts,
bone lining cells, osteoclasts and osteocytes.PTH stimulates bone formation by increasingthe number of osteoblasts, partly by delayingosteoblast apoptosis.21 Transient exposure tothis hormone, by injection of a short-half-life(13 h) preparation, results in distinct anaboliceffects. Continuous elevation of PTH levels,as seen in patients with hyperparathyroidism,usually results in catabolic effects and boneloss. The effects of PTH are mediated by aG-protein-coupled receptor, PTH receptor 1.
Different amino-terminal fragments of PTH,such as PTH131, could have a different ana-bolic effect to that of PTH134. Cyclic PTH131has been hypothesized to produce a more ana-bolic profile than PTH134 or PTH184 becausethe PTH131 doses that provide a robust bone-
formation response decrease bone resorption.A 12-month phase II dose-ranging trial in post-menopausal women demonstrated an increasein lumbar spine BMD of 11%.22 Selected aminoacid substitutions at various positions in PTH128have been shown to increase the activity of thishormone, suggesting that more-potent PTHligands might be available.23 Given that the dura-tion of PTH treatment is limited to 2 years in theUS and 18 months in Europe, there is an unmetneed for additional anabolic agents.
Modulators of calcium-sensing receptors
The calcium-sensing receptor is a G-protein-coupled, seven-pass transmembrane moleculepresent in the parathyroid gland (and kidney),whose function is to coordinate calcium homeo-stasis by regulating the release of PTH.24Manipulation of this receptor by small-moleculeallosteric modulators can affect PTH secre-tion. Positive allosteric modulatorscalcium-sensing-receptor agonists termed calcimimet-ics, such as cinacalcetare used to lessen PTHsecretion in patients with renal disease and hyper-parathyroidism. Negative allosteric modulatorscalcium-sensing-receptor antagonists termedcalcilyticsare in development for the treatmentof osteoporosis. These agents block the function ofcalcium-sensing receptors, resulting in a PTHpulse with each dose (Figure 3). Calcilytics canbe administered orally and would, therefore,remove the need for daily injections associatedwith teriparatide administration.
Calcilytics must meet several importantrequirements before they can be useful as ana-bolic agents. First, they must stimulate the releaseof sufficient PTH. Second, anabolic action
requires a short half-life and transient activa-tion of the receptor, since in the case of calcilyticssustained activation would result in prolongedPTH secretion and a catabolic state, such ashyperparathyroidism. Third, the moleculeshould not exhaust the parathyroid gland, whichwould result in hyperplasia. A proof of conceptstudy in rats with the calcilytic ronacaleret hasshown that this PTH agent has a short half-lifeand produces a robust PTH response, increasesboth cortical and trabecular bone formation,
Ca2+
Ca2+
Ca2+
Ca2+
Ca2+
Parathyroid cell
Calcium-sensing
receptor
Antagonist
PTH
Figur 3 Therapeutic manipulation of the calcium-
sensing receptor. The calcium-sensing receptor is
a G-coupled receptor that has an important role in
calcium homeostasis because of its expression on
parathyroid and kidney cells. Antagonism of the
receptor prevents binding of calcium and results in
the release of parathyroid hormone. Abbreviation:
PTH, parathyroid hormone.
review
http://www.nature.com/clinicalpractice/cardiohttp://www.nature.com/clinicalpractice/cardio7/28/2019 Nuevos Targets en Osteoporosis
6/8
jAnUARY 2009 vOL 5 nO 1 DEAL nature clinical practice RHEUMATOLOGY 25
www.nature.com/clinicalpractice/rheum
and generates notable increases in markersof osteoblast functionsuch as propeptide oftype I procollagen, osteocalcin and bone-specificalkaline phosphataseequivalent to those seenwith teriparatide. A dose-ranging clinical trialof ronacaleret in humans was discontinued,however, due to a poor effect on BMD.
Modulation of wnt signaling
Wnt proteins form a large family of extracellularcysteine-rich glycoproteins that help regulateembryogenetic bone remodeling and are involvedin many additional cellular processes.2527Wnt proteins activate an intracellular pathwaythat results in accumulation of beta-catenin.
Wnt permits association of the membrane recep-tors frizzled and lipoprotein-receptor-relatedprotein 5/6 (LRP5/6) and activation of a proteincomplex consisting of axin, adenomatous poly-posis coli and glycogen synthase kinase 3, whichactivates an intracellular pathway (Figure 4). Inthe absence of Wnt, glycogen synthase kinase 3phosphorylates beta-catenin, which is thendegraded via the ubiquitinproteosome pathway.In the presence of Wnt, the protein complex isdisrupted and phosphorylation of beta-catenin
does not occur, so beta-catenin accumulates,translocates to the cell nucleus and binds totranscription factors that affect transcription ofWnt-responsive genes, which are important inbone formation.
Inhibitors of Wnt signaling can bind to friz-zled (serum frizzled-related proteins), Wnt(Wnt inhibitory factors) or LRP5/6 (sclerostinand dickkopf-1). These agonist proteins preventWnt from activating the signaling pathwaymediated by frizzled and LRP5/6 receptor,leading to a decrease in signaling and a conse-quent reduction in bone formation. By contrast,deficiencies in these inhibitors or antibodiesresult in increased Wnt signaling and, therefore,
increased bone formation.Sclerosteosis, a human disease of high bone
mass, is the result of a homozygous mutationin the SOSTgene, which encodes sclerostin.28A deficiency of sclerostin results in increasedWnt signaling and high bone mass, and, in theskull, causes entrapment of cranial nerves andincreased intracranial pressure, which can subse-quently lead to stroke. Heterozygous mutations inthe SOST gene result in moderate increasesin bone mass and fewer skeletal complications.
Apc
Apc
A Without Wnt
-TRCP
Wnt
Axin
Gsk3
Ck1-Cat
Wnt-responsive gene
Fz
Lrp5/Lrp6
P P
TCF
B With Wnt
Axin
Gk3 -Cat
-Cat
-Cat
-Cat
Wnt-responsive gene
Fz
Lrp5/Lrp6
TCF
Dvl
Ck1
Figur 4 Simplified view or Wnt and beta-catenin signaling. (A) Without Wnt, the scaffolding protein
axin assembles a protein complex, beta-catenin is phosphorylated, ubiquitinated and degraded by the
proteosome. (B) With Wnt, beta-catenin is not phosphorylated, and is instead translocated to the nucleuswhere it binds to the TCF transcription factor, activating Wnt-responsive genes. Two membrane proteins,
Fz and LRP5/6, can associate in the presence of Wnt, which leads to formation of the protein scaffolding
complex, accumulation or degradation of -catenin, and gene transduction. Abbreviations:Apc, antigen presenting cell; -Cat, beta-catenin; -TRCP, transducin repeat-containing protein;Ck1, casein kinase 1; Dvl, disheveled; Fz, frizzled protein; GsK3, glycogen synthase kinase 3; LRP,
lipoprotein-receptor-related protein; TCF, T-cell factor. Reproduced with permission of the Company
of Biologists.
review
http://www.nature.com/clinicalpractice/cardiohttp://www.nature.com/clinicalpractice/cardio7/28/2019 Nuevos Targets en Osteoporosis
7/8
26 nature clinical practice RHEUMATOLOGY DEAL jAnUARY 2009 vOL 5 nO 1
www.nature.com/clinicalpractice/rheum
Given that sclerostin is almost exclusively aproduct of osteocytes, the development of anti-bodies to this protein offers a way to specificallytarget bone formation. Antibodies to sclerostinincrease bone formation in osteopenic estrogen-deficient rats.29 In postmenopausal women, a
single subcutaneous dose of an antibody tosclerostin resulted in a 60100% increase inthe levels of propeptide of type I procollagenat day 84 of treatment, no increase in serumC-telopeptides, and a 6% increase in lumbarspine BMD.29
Gain of function mutations in the gene encod-ing LRP5/6 lead to increased bone mass. Thesemutations impair binding of dickkopf-1 toLRP5/6 and permit increased Wnt signaling andbone formation. Antibodies against dickkopf-1prevent binding of dickkopf-1 to LRP5/6 and
increase bone mass, volume and formationin rodents. Antibodies to dickkopf-1 could beused as an anabolic agent for the treatment ofpatients with low bone mass.
Activin inhibitors
A key signaling component in bone forma-tion is bone morphogenic protein (BMP), amember of the transforming growth factor superfamily.30 BMPs signal via SMADs, whichare nuclear transcription factors that regulatethe activity of transforming growth factor betaligands and specific genes involved in osteo-genesis. Fibrodysplasia ossificans progressivea genetic disorder of progressive heterotopicossificationis caused by missense mutations inactivin receptor IA, a BMP type I receptor, andleads to increased BMP signaling.31 This signal-ing promotes osteoblast maturation and functionby binding to two distinct activin receptorsIand IIon the cell membrane. Activin binds toactivin receptor IIA and is a negative regulatorof bone mass, acting as an essential cofactor forosteoclastogenesis.
A fusion protein comprising the extracellular
domain of human activin receptor IIA andthe Fc portion of human IgG1 (ACE-011) hasthe capacity to bind to activin and preventreceptor binding. This antibody has beenshown to increase bone mass in cynomologusmonkeys (>70% increase in trabecular bonemass, as determined by quantitative CT).32Administration of a single dose of the fusionprotein to 48 postmenopausal women resultedin an increase in levels of bone-specific alkalinephosphatase and a decrease in C-telopeptides.33
The BMP pathway is a promising new area totarget therapeutic agents for the treatment oflow bone mass.
CONCLUSIONS
Notable advances in the treatment of low bone
mass seem to be on the horizon and are a resultof increased understanding of the mechanismsunderlying bone formation and resorption.New anabolic agents affecting the calcium-sensing receptor and Wnt signaling, and newantiresorptive agents that might have less of aneffect on bone formation than currently availabletherapies, offer promise for the treatment of lowbone mass. Additional therapies, especially thosethat can be used to treat patients with estab-lished fractures, are needed to reduce the burdenof osteoporosis.
KeY POINTS
Drugs that influence bone mass do so
by acting directly on cells that are integral to
the bone remodeling unit
Antiresorptive agents inhibit osteoclasts
and prevent bone resorption
Anabolic agents stimulate osteoblasts
and, therefore, bone formation
Potential new therapeutic agents include
denosumab, an antibody to receptor activator
of nuclear factor B ligand, and odanacatib,
a cathepsin K inhibitor
Potential new anabolic agents include those
that target the calcium-sensing receptor and
proteins in the Wnt signaling pathway
Rfrncs
1 McClung MR et al. (2005) Opposite bone remodeling
effects of teriparatide and alendronate in increasing
bone mass.Arch Intern Med165: 17621768
2 Khosla S et al. (2008) Building bone to reverse
osteoporosis and repair fractures.J Clin Invest
118: 421428
3 Kogianni G and Noble BS (2007) The biology
of osteocytes. Curr Osteoporos Rep 5: 8186
4 Odvina CV et al. (2005) Severely suppressed boneturnover: a potential complication of alendronate
therapy.J Clin Endocrinol Metab 90: 12941301
5 Vahle JL et al. (2002) Skeletal changes in rats given
daily subcutaneous injections of recombinant human
parathyroid hormone (134) for 2 years and relevance
to human safety. Toxicol Pathol30: 312321
6 McClung MR (2003) Bisphosphonates. Endocrinol
Metab Clin North Am 32: 253271
7 Russell RG et al. (2007) Bisphosphonates: an update
on mechanisms of action and how these relate to
clinical efficacy.Ann NY Acad Sci1117: 209257
8 Del Fattore Aet al. (2006) Clinical, genetic, and cellular
analysis of 49 osteopetrotic patients: implications for
diagnosis and treatment.J Med Genet43: 315325
review
http://www.nature.com/clinicalpractice/cardiohttp://www.nature.com/clinicalpractice/cardio7/28/2019 Nuevos Targets en Osteoporosis
8/8
jAnUARY 2009 vOL 5 nO 1 DEAL nature clinical practice RHEUMATOLOGY 27
www.nature.com/clinicalpractice/rheum
9 Henriksen DB et al. (2007) Disassociation of bone
resorption and formation by GLP-2: a 14-day study
in healthy postmenopausal women. Bone 40: 723729
10 Henriksen DB et al. (2007) GLP-2 significantly increases
hip BMD in postmenopausal women: a 120-day study
[abstract #1127]. Presented at the 29th Annual Meeting
of the American Society for Bone and Mineral Research:
2007 September 1620; Honolulu, HI
11 Henriksen DB et al. (2008) GLP-2 acutely
uncouples bone resorption and bone formation inpostmenopausal women [abstract #M399]. Presented
at the 30th Annual Meeting of the American Society for
Bone and Mineral Research: 2008 September 1216;
Montral, Quebc, Canada
12 Vasiljeva O et al. (2007) Emerging roles of cysteine
cathepsins in disease and their potential as drug
targets. Curr Pharm Des 13: 387403
13 Adami S et al. (2006) Effect of one year treatment with
the cathepsin-K inhibitor, balicatib, on bone mineral
density in postmenopausal women with osteopenia/
osteoporosis [abstract #1085]. Presented at the 28th
Annual Meeting of the American Society for Bone
and Mineral Research: 2006 September 1519;
Philadelphia, PA
14 Itabashi Aet al. (2006) Balicatib, a novel cathepsin-K
inhibitor, increases intact PTH beyond diurnalpatterns following 14-day administration in Japanese
postmenopausal women [abstract #1086]. Presented
at the 28th Annual Meeting of the American Society for
Bone and Mineral Research: 2006 September 1519;
Philadelphia, PA
15 McClung M et al. (2008) A randomized, double-blind,
placebo-controlled study of odanacatib (MK-822) in
the treatment of postmenopausal women with low
bone mineral density: 24-month results [abstract
#1291]. Presented at the 30th Annual Meeting of the
American Society for Bone and Mineral Research:
2008 September 1216; Montral, Quebc, Canada
16 Kearns AE et al. (2008) Receptor activator of nuclear
factor B ligand and osteoprotegerin regulation ofbone remodeling in health and disease. Endocr Rev
29: 155192
17 Hamdy NA (2008) Denosumab: RANKL inhibitionin the management of bone loss. Drugs Today (Barc)
44: 721
18 Lewiecki EM et al. (2007) Two-year treatment with
denosumab (AMG 162) in a randomized phase 2 study
of postmenopausal women with low BMD.
J Bone Miner Res 22: 18321841
19 Cummings SR et al. (2008) A phase III study
of the effects of denosumab on vertebral, nonvertebral,
and hip fracture in women with osteoporosis: results
from the FREEDOM Trial [abstract #1286]. Presented
at the 30th Annual Meeting of the American Society for
Bone and Mineral Research: 2008 September 1216;
Montral, Quebc, Canada
20 Neer RM et al. (2001) Effect of parathyroid
hormone (134) on fractures and bone mineral density
in postmenopausal women with osteoporosis. N Engl JMed344: 14341441
21 Jilka RL (2007) Molecular and cellular mechanisms
of the anabolic effect of intermittent PTH. Bone 40:
14341446
22 MacDonald B et al. (2008) An active controlled,
non-inferiority study to compare the effect of ZT-031
with alendronate on the incidence of new vertebral
fractures: the PACE (cyclic PTH and alendronate
comparative efficacy) study [abstract #M347].
Presented at the 30th Annual Meeting of the American
Society for Bone and Mineral Research:2008 September 1216; Montral, Quebc, Canada
23 Okazaki M et al. (2008) Identification and optimization
of residues in PTH and PTHrP that determine altered
modes of binding to the PTH/PTHrP receptor.
Presented at the 30th Annual Meeting of the American
Society for Bone and Mineral Research:
2008 September 1216; Montral, Quebc, Canada
24 Brown EM (2007) The calcium-sensing receptor:
physiology, pathophysiology and CaR-based
therapeutics.Subcell Biochem 45: 139167
25 Glass DA II and Karsenty G (2007) In vivo analysis
of Wnt signaling in bone. Endocrinology148:
26302634
26 Krishnan V et al. (2006) Regulation of bone mass by
Wnt signaling.J Clin Invest116: 12021209
27 Baron R and Rawadi G (2007) Targeting the Wnt/beta-catenin pathway to regulate bone formation
in the adult skeleton. Endocrinology148: 26352643
28 Gardner JC et al. (2005) Bone mineral density in
sclerosteosis; affected individuals and gene carriers.
J Clin Endocrinol Metab 90: 63926395
29 Padhi D et al. (2007) Anti-sclerostin antibody
increases markers of bone formation in healthy
postmenopausal women [abstract #1129]. Presented
at the 29th Annual Meeting of the American Society
for Bone and Mineral Research: 2007 September
1620; Honolulu, HI
30 Canalis E et al. (2003) Bone morphogenetic proteins,
their antagonists, and the skeleton. Endocr Rev24:
218235
31 Billings PC et al. (2008) Dysregulated BMP signaling
and enhanced osteogenic differentiation of
connective tissue progenitor cells from patients withfibrodysplasia ossificans progressiva (FOP). Presented
at the 30th Annual Meeting of the American Society
for Bone and Mineral Research: 2008 September
1216; Montral, Quebc, Canada
32 Fajardo RJ et al. (2008) ACE-011, a soluble activin
receptor type IIA fusion protena increases BMD and
improves microarchitecture in cynomolgus monkeys
[abstract #1230]. Presented at the 29th Annual
Meeting of the American Society for Bone and Mineral
Research: 2007 September 1620; Honolulu, HI
33 Ruckle J et al. (2007) A single dose of ACE-011 is
associated with increases in bone formation and
decreases in bone resorption markers in healthy
postmenopausal women [abstract #1132]. Presented
at the 29th Annual Meeting of the American Society for
Bone and Mineral Research: 2007 September 1620;Honolulu, HI
Compting intrstsC Deal has declared
associations with the
following companies:
Amgen, GSK, Lilly, Novartis,
Proctor & Gamble and
Roche. See the article
online for full details
of the relationships.
review
http://www.nature.com/clinicalpractice/cardiohttp://www.nature.com/clinicalpractice/cardio